{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:59:36Z","timestamp":1780916376080,"version":"3.54.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["82104507"],"award-info":[{"award-number":["82104507"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Hospital Foundation of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","award":["2024A05"],"award-info":[{"award-number":["2024A05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease lacking FDA-approved therapy.\n                      <jats:italic>Calculus Bovis<\/jats:italic>\n                      (CB), a traditional medicine derived from animal gallstones, has been historically used for treating hepatobiliary diseases, but its therapeutic potential and mechanisms in PSC remain unexplored. This study aimed to investigate the efficacy of CB in an experimental PSC model and elucidate its underlying mechanisms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A PSC mouse model was induced by a 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet for 4\u00a0weeks. Mice were treated with CB (50,100, 150\u00a0mg\/kg\/day) or ursodeoxycholic acid (UDCA, 100\u00a0mg\/kg\/day). Liver injury, fibrosis, intestinal barrier integrity, bile acid (BA) profiles, and lipid levels were assessed. Hepatic and intestinal gene\/protein expression related to BA and lipid metabolism was analyzed. Integrated transcriptomics, network pharmacology, and\n                      <jats:italic>in vitro<\/jats:italic>\n                      serum pharmacology were employed to elucidate the underlying mechanisms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CB administration significantly alleviated liver injury, fibrosis, and intestinal barrier damage in DDC-induced mice. It restored BA homeostasis across the gut-liver axis, normalizing aberrant BA profiles in serum and liver while increasing BA excretion in feces. CB also ameliorated dyslipidemia, reducing hepatic and serum lipid levels. Mechanistically, CB and its bioactive BA components exerted their effects through a dual-pronged mechanism: (1) activation of the SIRT1-PGC-1\u03b1 axis to transcriptionally upregulate the expression of nuclear receptors FXR and PPAR\u03b1 in the liver and intestine, and (2) direct ligand-dependent activation of FXR and PPAR\u03b1 protein functions. This concerted activation enhanced the transcription of genes involved in BA detoxification, transport, and fatty acid \u03b2-oxidation. Inhibition of SIRT1 or antagonism of FXR\/PPAR\u03b1 attenuated these protective effects\n                      <jats:italic>in vitro<\/jats:italic>\n                      <jats:italic>.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CB attenuates experimental PSC by modulating BA and lipid homeostasis via the gut-liver axis, mediated through a novel dual mechanism involving SIRT1-PGC-1\u03b1 pathway activation and direct receptor agonism. These findings not only highlight CB as a promising multi-target agent for PSC treatment, but also provide novel insights into the therapeutic modulation of metabolism in the gut-liver axis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-026-01441-w","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:05:07Z","timestamp":1780913107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Calculus Bovis ameliorates primary sclerosing cholangitis via a dual-pronged mechanism restoring bile acid and lipid homeostasis in the gut-liver axis"],"prefix":"10.1186","volume":"21","author":[{"given":"Xuepeng","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninghong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaoqin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"2","key":"1441_CR1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hep.32771","volume":"77","author":"CL Bowlus","year":"2023","unstructured":"Bowlus CL, Arriv\u00e9 L, Bergquist A, Deneau M, Forman L, Ilyas SI, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023;77(2):659\u2013702.","journal-title":"Hepatology"},{"key":"1441_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jhep.2023.09.031","volume":"180","author":"KN van Munster","year":"2024","unstructured":"van Munster KN, Bergquist A, Ponsioen CY. Inflammatory bowel disease and primary sclerosing cholangitis: One disease or two? J Hepatol. 2024;180:155\u201368. https:\/\/doi.org\/10.1016\/j.jhep.2023.09.031.","journal-title":"J Hepatol"},{"key":"1441_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322362","author":"PJ Trivedi","year":"2021","unstructured":"Trivedi PJ, Hirschfield GM. Recent advances in clinical practice: Epidemiology of autoimmune liver diseases. Gut. 2021. https:\/\/doi.org\/10.1136\/gutjnl-2020-322362.","journal-title":"Gut"},{"key":"1441_CR4","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.cgh.2023.04.004","volume":"821","author":"DN Assis","year":"2023","unstructured":"Assis DN, Bowlus CL. Recent advances in the management of primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2023;821:2065\u201375. https:\/\/doi.org\/10.1016\/j.cgh.2023.04.004.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1441_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00690-y","author":"JR Hov","year":"2023","unstructured":"Hov JR, Karlsen TH. The microbiota and the gut-liver axis in primary sclerosing cholangitis. Nat Rev Gastroenterol Hepatol. 2023. https:\/\/doi.org\/10.1038\/s41575-022-00690-y.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1441_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2022.02.004","author":"J Cai","year":"2022","unstructured":"Cai J, Sun L, Gonzalez FJ. Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis. Cell Host Microbe. 2022. https:\/\/doi.org\/10.1016\/j.chom.2022.02.004.","journal-title":"Cell Host Microbe"},{"key":"1441_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-00914-3","author":"I Mohanty","year":"2024","unstructured":"Mohanty I, Allaband C, Mannochio-Russo H, El Abiead Y, Hagey LR, Knight R, et al. The changing metabolic landscape of bile acids - keys to metabolism and immune regulation. Nat Rev Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1038\/s41575-024-00914-3.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"1441_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/HEP.0000000000000611","volume":"79","author":"Y Zhuang","year":"2024","unstructured":"Zhuang Y, Ortega-Ribera M, Nagesh PT, Joshi R, Huang H, Wang Y, et al. Bile acid\u2013induced IRF3 phosphorylation mediates cell death, inflammatory responses, and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1. Hepatology. 2024;79(4):752\u201367.","journal-title":"Hepatology"},{"key":"1441_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00600-x","author":"MP Manns","year":"2025","unstructured":"Manns MP, Bergquist A, Karlsen TH, Levy C, Muir AJ, Ponsioen C, et al. Primary sclerosing cholangitis. Nat Rev Dis Primers. 2025. https:\/\/doi.org\/10.1038\/s41572-025-00600-x.","journal-title":"Nat Rev Dis Primers"},{"key":"1441_CR10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.1677","author":"MJ Perez","year":"2009","unstructured":"Perez MJ, Briz O. Bile-acid-induced cell injury and protection. World J Gastroenterol. 2009. https:\/\/doi.org\/10.3748\/wjg.15.1677.","journal-title":"World J Gastroenterol"},{"key":"1441_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1607899","volume":"12","author":"G Song","year":"2025","unstructured":"Song G, Xie Y, Yi L, Cheng W, Jia H, Shi W, et al. Bile acids affect intestinal barrier function through FXR and TGR5. Front Med. 2025;12:1607899. https:\/\/doi.org\/10.3389\/fmed.2025.1607899.","journal-title":"Front Med"},{"key":"1441_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108238","volume":"237","author":"J Cai","year":"2022","unstructured":"Cai J, Rimal B, Jiang C, Chiang JYL, Patterson AD. Bile acid metabolism and signaling, the microbiota, and metabolic disease. Pharmacol Ther. 2022;237:108238. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108238.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"1441_CR13","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.bbadis.2017.09.019","volume":"1864","author":"M Cariello","year":"2018","unstructured":"Cariello M, Piccinin E, Garcia-Irigoyen O, Sabb\u00e0 C, Moschetta A. Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations. Biochimica et Biophysica Acta Molecular Basis Dis. 2018;1864(4):1308\u201318.","journal-title":"Biochimica et Biophysica Acta Molecular Basis Dis."},{"key":"1441_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.916866","volume":"13","author":"X Ye","year":"2022","unstructured":"Ye X, Zhang T, Han H. PPARalpha: A potential therapeutic target of cholestasis. Front Pharmacol. 2022;13:916866. https:\/\/doi.org\/10.3389\/fphar.2022.916866.","journal-title":"Front Pharmacol"},{"key":"1441_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","volume":"173","author":"KV Kowdley","year":"2020","unstructured":"Kowdley KV, Vuppalanchi R, Levy C, Floreani A, Andreone P, LaRusso NF, et al. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J Hepatol. 2020;173:94\u2013101. https:\/\/doi.org\/10.1016\/j.jhep.2020.02.033.","journal-title":"J Hepatol"},{"key":"1441_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.984","volume":"410","author":"B Hatami","year":"2022","unstructured":"Hatami B, Mosala M, Hassani AH, Ardakani MJE, Gholami S, Zali MR. Fenofibrate in primary sclerosing cholangitis; A randomized, double-blind, placebo-controlled trial. Pharmacol Res Perspect. 2022;410:e984. https:\/\/doi.org\/10.1002\/prp2.984.","journal-title":"Pharmacol Res Perspect"},{"key":"1441_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.112649","volume":"254","author":"ZJ Yu","year":"2020","unstructured":"Yu ZJ, Xu Y, Peng W, Liu YJ, Zhang JM, Li JS, et al. Calculus bovis: A review of the traditional usages, origin, chemistry, pharmacological activities and toxicology. J Ethnopharmacol. 2020;254:112649. https:\/\/doi.org\/10.1016\/j.jep.2020.112649.","journal-title":"J Ethnopharmacol"},{"issue":"302","key":"1441_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.115854","volume":"10","author":"D Xiang","year":"2023","unstructured":"Xiang D, Liu Y, Zu Y, Yang J, He W, Zhang C, et al. Calculus Bovis Sativus alleviates estrogen cholestasis-induced gut and liver injury in rats by regulating inflammation, oxidative stress, apoptosis, and bile acid profiles. J Ethnopharmacol. 2023;10(302):115854.","journal-title":"J Ethnopharmacol"},{"key":"1441_CR19","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1142\/S0192415X13500936","volume":"641","author":"T Wu","year":"2013","unstructured":"Wu T, Chang M, Xu Y, Li X, Du G, Liu D. Protective effect of Calculus Bovis Sativus on intrahepatic cholestasis in rats induced by \u03b1-naphthylisothiocyanate. Am J Chin Med. 2013;641:1393\u2013405. https:\/\/doi.org\/10.1142\/S0192415X13500936.","journal-title":"Am J Chin Med"},{"issue":"3","key":"1441_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202517864","volume":"65","author":"HC Lin","year":"2026","unstructured":"Lin HC, Shen WY, Wei JH, Chen LL, Jia CP, Mo ZY, et al. Rhodium (III)-Nitroxyl radical complex triggers dual-pronged disulfidptosis-apoptosis in hepatocellular carcinoma via metabolic sabotage and redox catalysis. Angewandte Chemie Int Edit. 2026;65(3):e17864.","journal-title":"Angewandte Chemie Int Edit."},{"issue":"5573","key":"1441_CR21","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1126\/science.1072891","volume":"296","author":"NL Urizar","year":"2002","unstructured":"Urizar NL, Liverman AB, Dodds DN, Silva FV, Ordentlich P, Yan Y, et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 2002;296(5573):1703\u20136.","journal-title":"Science"},{"key":"1441_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/483536","volume":"2012","author":"MDC Gonz\u00e1lez","year":"2012","unstructured":"Gonz\u00e1lez MDC, Corton JC, Acero N, Mu Oz-Mingarro D, Quir\u00f3s Y, Alvarez-Mill\u00e1n JJ, et al. Peroxisome proliferator-activated receptor\u03b1 agonists differentially regulate inhibitor of DNA binding expression in rodents and human cells. Ppar Res. 2012;2012:483536. https:\/\/doi.org\/10.1155\/2012\/483536.","journal-title":"Ppar Res"},{"key":"1441_CR23","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1136\/gut.33.5.622","volume":"533","author":"VC Dias","year":"1992","unstructured":"Dias VC, Wallace JL, Parsons HG. Modulation of cellular phospholipid fatty acids and leukotriene B4 synthesis in the human intestinal cell (CaCo-2). Gut. 1992;533:622\u20137. https:\/\/doi.org\/10.1136\/gut.33.5.622.","journal-title":"Gut"},{"key":"1441_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116639","volume":"255","author":"X Gong","year":"2025","unstructured":"Gong X, Liu D, Liu L, Yang G, Lei Y, Li N, et al. Plasma bile acid profile analysis by liquid chromatography-tandem mass spectrometry and its application in healthy subjects and IBD patients. J Pharm Biomed Anal. 2025;255:116639. https:\/\/doi.org\/10.1016\/j.jpba.2024.116639.","journal-title":"J Pharm Biomed Anal"},{"key":"1441_CR25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jhep.2024.09.032","volume":"182","author":"CD Fuchs","year":"2025","unstructured":"Fuchs CD, Simbrunner B, Baumgartner M, Campbell C, Reiberger T, Trauner M. Bile acid metabolism and signalling in liver disease. J Hepatol. 2025;182:134\u201353. https:\/\/doi.org\/10.1016\/j.jhep.2024.09.032.","journal-title":"J Hepatol"},{"key":"1441_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115606","volume":"168","author":"D Xiang","year":"2023","unstructured":"Xiang D, Yang J, Liu L, Yu H, Gong X, Liu D. The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis. Biomed Pharmacother. 2023;168:115606. https:\/\/doi.org\/10.1016\/j.biopha.2023.115606.","journal-title":"Biomed Pharmacother"},{"key":"1441_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.01.039","author":"L Zheng","year":"2024","unstructured":"Zheng L, Tian S, Yang C, Li B, Jia G, Liu Y, et al. Hypercholesterolemia is associated with dysregulation of lipid metabolism and poor prognosis in primary biliary cholangitis. Clin Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.cgh.2024.01.039.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1441_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","volume":"152","author":"Z Chen","year":"2020","unstructured":"Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020;152:116\u201341. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.02.025.","journal-title":"Free Radic Biol Med"},{"key":"1441_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1101\/gad.1138104","volume":"218","author":"Y Zhang","year":"2004","unstructured":"Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev. 2004;218:157\u201369. https:\/\/doi.org\/10.1101\/gad.1138104.","journal-title":"Genes Dev"},{"issue":"12","key":"1441_CR30","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.3390\/cells10123550","volume":"10","author":"R Shizu","year":"2021","unstructured":"Shizu R, Ezaki K, Sato T, Sugawara A, Hosaka T, Sasaki T, et al. PXR suppresses PPAR\u03b1-dependent HMGCS2 gene transcription by inhibiting the interaction between PPAR\u03b1 and PGC1\u03b1. Cells. 2021;10(12):3550.","journal-title":"Cells"},{"key":"1441_CR31","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2006.11.013","volume":"6127","author":"M Lagouge","year":"2006","unstructured":"Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;6127:1109\u201322. https:\/\/doi.org\/10.1016\/j.cell.2006.11.013.","journal-title":"Cell"},{"key":"1441_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2009.11.023","author":"JJ Dominy","year":"2010","unstructured":"Dominy JJ, Lee Y, Gerhart-Hines Z, Puigserver P. Nutrient-dependent regulation of PGC-1\u03b1\u2019s acetylation state and metabolic function through the enzymatic activities of Sirt1\/GCN5. Biochim Biophys Acta. 2010. https:\/\/doi.org\/10.1016\/j.bbapap.2009.11.023.","journal-title":"Biochim Biophys Acta"},{"key":"1441_CR33","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cphy.c120023","volume":"33","author":"JYL Chiang","year":"2013","unstructured":"Chiang JYL. Bile acid metabolism and signaling. Compr Physiol. 2013;33:1191\u2013212. https:\/\/doi.org\/10.1002\/cphy.c120023.","journal-title":"Compr Physiol"},{"issue":"253","key":"1441_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.127308","volume":"31","author":"R Zhao","year":"2023","unstructured":"Zhao R, Ji Y, Chen X, Ma G, Yao H, Li J, et al. Flammulina velutipes polysaccharides regulate lipid metabolism disorders in HFD-fed mice via bile acids metabolism. Int J Bio Macromol. 2023;31(253):127308.","journal-title":"Int J Bio Macromol."},{"key":"1441_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41061-8","author":"J Zhong","year":"2023","unstructured":"Zhong J, He X, Gao X, Liu Q, Zhao Y, Hong Y, et al. Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPAR\u03b1 nucleus-cytoplasm shuttling. Nat Commun. 2023. https:\/\/doi.org\/10.1038\/s41467-023-41061-8.","journal-title":"Nat Commun"},{"key":"1441_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31652","author":"OY Mousa","year":"2021","unstructured":"Mousa OY, Juran BD, McCauley BM, Vesterhus MN, Folseraas T, Turgeon CT, et al. Bile acid profiles in primary sclerosing cholangitis and their ability to predict hepatic decompensation. Hepatology. 2021. https:\/\/doi.org\/10.1002\/hep.31652.","journal-title":"Hepatology"},{"issue":"6","key":"1441_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000452","volume":"8","author":"A Kayashima","year":"2024","unstructured":"Kayashima A, Sujino T, Fukuhara S, Miyamoto K, Kubosawa Y, Ichikawa M, et al. Unique bile acid profiles in the bile ducts of patients with primary sclerosing cholangitis. Hepatology Communications. 2024;8(6):e0452.","journal-title":"Hepatology Communications"},{"key":"1441_CR38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1177\/2050640617708953","volume":"16","author":"J Torres","year":"2018","unstructured":"Torres J, Palmela C, Brito H, Bao X, Ruiqi H, Moura-Santos P, et al. The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. United European Gastroenterol J. 2018;16:112\u201322. https:\/\/doi.org\/10.1177\/2050640617708953.","journal-title":"United European Gastroenterol J"},{"key":"1441_CR39","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/liv.12680","volume":"135","author":"LN Bell","year":"2015","unstructured":"Bell LN, Wulff J, Comerford M, Vuppalanchi R, Chalasani N. Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis. Liver Int. 2015;135:263\u201374. https:\/\/doi.org\/10.1111\/liv.12680.","journal-title":"Liver Int"},{"issue":"12","key":"1441_CR40","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.3390\/biomedicines10123046","volume":"10","author":"VI Reshetnyak","year":"2022","unstructured":"Reshetnyak VI, Maev IV. Features of lipid metabolism disorders in primary biliary cholangitis. Biomedicines. 2022;10(12):3046.","journal-title":"Biomedicines."},{"key":"1441_CR41","doi-asserted-by":"publisher","first-page":"24784","DOI":"10.1074\/jbc.M111.329318","volume":"29287","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Li F, Patterson AD, Wang Y, Krausz KW, Neale G, et al. Abcb11 deficiency induces cholestasis coupled to impaired beta-fatty acid oxidation in mice. J Biol Chem. 2012;29287:24784\u201394. https:\/\/doi.org\/10.1074\/jbc.M111.329318.","journal-title":"J Biol Chem"},{"key":"1441_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2025.159642","volume":"61870","author":"Z Xu","year":"2025","unstructured":"Xu Z, Cao X, Zhu Z, Lei J, Li L, Zhang X, et al. Tumor necrosis factor alpha-induced activation of SREBP2 promotes cholesterol biosynthesis in cholestasis. Biochim Biophys Acta Mol Cell Biol Lipids. 2025;61870:159642. https:\/\/doi.org\/10.1016\/j.bbalip.2025.159642.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"1441_CR43","doi-asserted-by":"publisher","DOI":"10.26599\/FSHW.2025.9250908","author":"J Jia","year":"2026","unstructured":"Jia J, Zhai S, Cai T, Guo P, Yang G, Chang Z, et al. Rutin alleviates high-fat diet-induced MAFLD: insights from 16S rRNA sequencing, metabolome, network pharmacology and transcriptome analyses. Food Sci Human Wellness. 2026. https:\/\/doi.org\/10.26599\/FSHW.2025.9250908.","journal-title":"Food Sci Human Wellness"},{"key":"1441_CR44","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1210\/er.2018-00064","volume":"539","author":"N Bougarne","year":"2018","unstructured":"Bougarne N, Weyers B, Desmet SJ, Deckers J, Ray DW, Staels B, et al. Molecular actions of PPARalpha in lipid metabolism and inflammation. Endocr Rev. 2018;539:760\u2013802. https:\/\/doi.org\/10.1210\/er.2018-00064.","journal-title":"Endocr Rev"},{"key":"1441_CR45","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/hep.32538","volume":"177","author":"T Yan","year":"2023","unstructured":"Yan T, Luo Y, Yan N, Hamada K, Zhao N, Xia Y, et al. Intestinal peroxisome proliferator-activated receptor alpha-fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis. Hepatology. 2023;177:239\u201355. https:\/\/doi.org\/10.1002\/hep.32538.","journal-title":"Hepatology"},{"key":"1441_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2021.100150","volume":"62","author":"S Kersten","year":"2021","unstructured":"Kersten S. Role and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma lipid metabolism. J Lipid Res. 2021;62:100150. https:\/\/doi.org\/10.1016\/j.jlr.2021.100150.","journal-title":"J Lipid Res"},{"key":"1441_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27744","author":"NS Ghonem","year":"2015","unstructured":"Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology. 2015. https:\/\/doi.org\/10.1002\/hep.27744.","journal-title":"Hepatology"},{"key":"1441_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113577","volume":"154","author":"S Zhou","year":"2022","unstructured":"Zhou S, You H, Qiu S, Yu D, Bai Y, He J, et al. A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARalpha) and farnesoid X receptor (FXR). Biomed Pharmacother. 2022;154:113577. https:\/\/doi.org\/10.1016\/j.biopha.2022.113577.","journal-title":"Biomed Pharmacother"},{"key":"1441_CR49","doi-asserted-by":"publisher","first-page":"8732","DOI":"10.1074\/jbc.RA119.008360","volume":"22294","author":"S Byun","year":"2019","unstructured":"Byun S, Jung H, Chen J, Kim YC, Kim DH, Kong B, et al. Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis. J Biol Chem. 2019;22294:8732\u201344. https:\/\/doi.org\/10.1074\/jbc.RA119.008360.","journal-title":"J Biol Chem"},{"key":"1441_CR50","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1194\/jlr.M027433","volume":"853","author":"F Li","year":"2012","unstructured":"Li F, Patterson AD, Krausz KW, Tanaka N, Gonzalez FJ. Metabolomics reveals an essential role for peroxisome proliferator-activated receptor alpha in bile acid homeostasis. J Lipid Res. 2012;853:1625\u201335. https:\/\/doi.org\/10.1194\/jlr.M027433.","journal-title":"J Lipid Res"},{"key":"1441_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10524-6","volume":"17","author":"Q Zhao","year":"2017","unstructured":"Zhao Q, Yang R, Wang J, Hu DD, Li F. PPARalpha activation protects against cholestatic liver injury. Sci Rep. 2017;17:9967. https:\/\/doi.org\/10.1038\/s41598-017-10524-6.","journal-title":"Sci Rep"},{"key":"1441_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122355","volume":"337","author":"Q Lu","year":"2024","unstructured":"Lu Q, Zhu Y, Wang C, Zhang R, Miao Y, Chai Y, et al. Obeticholic acid protects against lithocholic acid-induced exogenous cell apoptosis during cholestatic liver injury. Life Sci. 2024;337:122355. https:\/\/doi.org\/10.1016\/j.lfs.2023.122355.","journal-title":"Life Sci"},{"key":"1441_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2013.12.001","author":"HC Chang","year":"2014","unstructured":"Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab. 2014. https:\/\/doi.org\/10.1016\/j.tem.2013.12.001.","journal-title":"Trends Endocrinol Metab"},{"key":"1441_CR54","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3109\/07853890.2010.547211","volume":"343","author":"TT Schug","year":"2011","unstructured":"Schug TT, Li X. Sirtuin 1 in lipid metabolism and obesity. Ann Med. 2011;343:198\u2013211. https:\/\/doi.org\/10.3109\/07853890.2010.547211.","journal-title":"Ann Med"},{"key":"1441_CR55","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/B978-0-12-407766-9.00016-X","volume":"91","author":"JK Kemper","year":"2013","unstructured":"Kemper JK, Choi SE, Kim DH. Sirtuin 1 deacetylase: a key regulator of hepatic lipid metabolism. Vitam Horm. 2013;91:385\u2013404. https:\/\/doi.org\/10.1016\/B978-0-12-407766-9.00016-X.","journal-title":"Vitam Horm"},{"key":"1441_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28826","author":"SR Kulkarni","year":"2016","unstructured":"Kulkarni SR, Soroka CJ, Hagey LR, Boyer JL. Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis. Hepatology. 2016. https:\/\/doi.org\/10.1002\/hep.28826.","journal-title":"Hepatology"},{"key":"1441_CR57","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jhep.2012.08.008","volume":"158","author":"RE Castro","year":"2013","unstructured":"Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV, Cortez-Pinto H, et al. MiR-34a\/SIRT1\/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol. 2013;158:119\u201325. https:\/\/doi.org\/10.1016\/j.jhep.2012.08.008.","journal-title":"J Hepatol"},{"key":"1441_CR58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0802917105","author":"PT Pfluger","year":"2008","unstructured":"Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A. 2008. https:\/\/doi.org\/10.1073\/pnas.0802917105.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1441_CR59","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature03354","volume":"7029434","author":"JT Rodgers","year":"2005","unstructured":"Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 2005;7029434:113\u20138. https:\/\/doi.org\/10.1038\/nature03354.","journal-title":"Nature"},{"key":"1441_CR60","doi-asserted-by":"publisher","first-page":"29244","DOI":"10.1038\/s41598-024-80119-5","volume":"114","author":"M Taghizadeh","year":"2024","unstructured":"Taghizadeh M, Maleki MH, Vakili O, Tavakoli R, Zarei P, Dehghanian A, et al. Bilirubin, a hepatoprotective agent that activates SIRT1, PGC-1\u03b1,?and PPAR-\u03b1, while inhibiting NF-\u03baB in rats with metabolic-associated fatty liver disease. Sci Rep-Uk. 2024;114:29244. https:\/\/doi.org\/10.1038\/s41598-024-80119-5.","journal-title":"Sci Rep-Uk"},{"key":"1441_CR61","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00018-025-05680-2","volume":"182","author":"N Wu","year":"2025","unstructured":"Wu N, Jiang X, Liu Y, Zhang M, Yue M, Chen F, et al. Glycodeoxycholic acid alleviates central precocious puberty by modulating gut microbiota and metabolites in high-fat diet-fed female rats. Cellular Molec Life Sci\u202f: CMLS. 2025;182:163. https:\/\/doi.org\/10.1007\/s00018-025-05680-2.","journal-title":"Cellular Molec Life Sci : CMLS"},{"key":"1441_CR62","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.3748\/wjg.v28.i31.4338","volume":"3128","author":"H Han","year":"2022","unstructured":"Han H, Liu S, Zhang X, Wei M, Huang X, Yu W. Duodenal-jejunal bypass increases intraduodenal bile acids and upregulates duodenal SIRT1 expression in high-fat diet and streptozotocin-induced diabetic rats. World J Gastroentero. 2022;3128:4338\u201350. https:\/\/doi.org\/10.3748\/wjg.v28.i31.4338.","journal-title":"World J Gastroentero"},{"key":"1441_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.06.010","author":"U Beuers","year":"2025","unstructured":"Beuers U, Banales JM, Karpen SJ, Keitel V, Williamson C, Trauner M. The history and future of bile acid therapies. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.06.010.","journal-title":"J Hepatol"},{"key":"1441_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324305","author":"M Trauner","year":"2022","unstructured":"Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut. 2022. https:\/\/doi.org\/10.1136\/gutjnl-2021-324305.","journal-title":"Gut"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01441-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-026-01441-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01441-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:05:09Z","timestamp":1780913109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-026-01441-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1441"],"URL":"https:\/\/doi.org\/10.1186\/s13020-026-01441-w","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted following approval from the Experimental Animal Welfare and Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (Approval number: TJH-202311030).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}